Silo Pharma Inc. (NASDAQ: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' (AMD) AI Developer Program. This membership provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community, which the company expects will accelerate the development, testing, optimization, and deployment of its AI agent platform across consumer and enterprise applications.
QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding, and workflow automation. Silo said participation in the AMD AI Developer Program is expected to support platform performance, agent reliability, and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses, and enterprise customers.
This development is significant for Silo Pharma as it diversifies beyond its core biopharmaceutical focus. The company, a diversified developmental-stage biopharmaceutical and cryptocurrency treasury firm, targets underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets for Alzheimer's disease and multiple sclerosis. By joining the AMD program, Silo positions QwikAgents to leverage advanced AI infrastructure, potentially enhancing its competitive edge in the rapidly growing AI agent market.
The implications for the industry are notable. AI agents are increasingly used to automate complex tasks, and access to AMD's developer ecosystem could help QwikAgents optimize its platform for performance and scalability. For readers, this news highlights the convergence of biotech and AI, as Silo applies cutting-edge computing to its technology stack. While the immediate impact on Silo's financials remains to be seen, the partnership may accelerate product development and attract enterprise clients.
For more details, the full press release is available at https://ibn.fm/313SC. Additional updates on Silo Pharma can be found in the company's newsroom at https://ibn.fm/SILO.
